REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
1 hedge funds and large institutions have $44K invested in REGENERX BIOPHARMACEUTICALS in 2016 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
22% more capital invested
Capital invested by funds: $36K → $44K (+$8K)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BMO
Beck Mack & Oliver
New York
|
-$8K |
RGN Hedge Fund Activity: Q1 2016 in Review
1 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q1 2016, worth a combined $44K — up 22% from $36K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RGN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Beck Mack & Oliver, exiting entirely with an estimated $8K sold.
- 1 institutional investor held REGENERX BIOPHARMACEUTICALS (RGN) as of Q1 2016, down from 2 in Q4 2015.
- Funds reported $44K of REGENERX BIOPHARMACEUTICALS stock for Q1 2016, up 22% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q1 2016 and 1 closed out, a net change of -1 holder.
- The largest REGENERX BIOPHARMACEUTICALS seller in Q1 2016 was Beck Mack & Oliver, an estimated $8K sold.
Based on aggregated 13F filings for Q1 2016.